CRISPR Therapeutics to Host Conference Call and Webcast to Provide an Update on the CRISPR/Cas9 U.S. Patent Interference Proceedings and Corresponding U.K. Patents
BASEL, Switzerland and CAMBRIDGE, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that management will host a conference call and live audio webcast on Thursday, February 16, 2017 at 11:00 a.m. ET to provide an update on the CRISPR/Cas9 U.S. Patent Interference Proceedings as well as an update on the corresponding U.K. patents.
To access the conference call, please dial +1 (844) 358-8762 (domestic) or +1 (703) 736-7374 (international) and reference the conference ID number 74645402. To join the live webcast, please visit the “Investors & Media” section of the CRISPR Therapeutics website at www.crisprtx.com.
A webcast replay will be available on the CRISPR Therapeutics website beginning approximately two hours after the event and will be archived for 30 days.
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the Company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.
MEDIA CONTACTS: Jennifer PaganelliW2O Group for CRISPR 347-658-8290 email@example.com INVESTOR CONTACT: Chris BrinzeyWestwicke Partners for CRISPR 339-970-2843 firstname.lastname@example.org